American Association for Cancer Research
Browse
00085472can152555-sup-155528_2_supp_0_t6mtkt.pdf (136.89 kB)

Supplementary Methods and Reference from Dicer Elicits Paclitaxel Chemosensitization and Suppresses Cancer Stemness in Breast Cancer by Repressing AXL

Download (136.89 kB)
journal contribution
posted on 2023-03-30, 23:40 authored by Ting-Yu Chang, Hsin-An Chen, Ching-Feng Chiu, Yi-Wen Chang, Tsang-Chih Kuo, Po-Chun Tseng, Weu Wang, Mien-Chie Hung, Jen-Liang Su

Description of additional methods and procedures used in the study. Also includes Supplementary Reference.

Funding

Ministry of Science and Technology (National Science Council) grants from Taiwan

National Health Research Institutes grant from Taiwan

Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare grant from Taiwan

History

ARTICLE ABSTRACT

Paclitaxel is a standard-of-care chemotherapy for breast cancer, despite the increasing recognition of its poor effectiveness in the treatment of patients with advanced disease. Here, we report that adenovirus-type 5 E1A-mediated elevation of the miRNA-processing enzyme Dicer is sufficient to enhance paclitaxel sensitization and reduce cancer stem-like cell properties in this setting. Elevating Dicer expression increased levels of the AXL kinase targeting miRNA miR-494, thereby repressing AXL expression to increase paclitaxel sensitivity. We found that Dicer expression was regulated at the transcription level by E1A, through activation of an MAPK14/CEBPα pathway. Our findings define a mechanism of E1A-mediated chemosensitization for paclitaxel, which is based upon the suppression of breast cancer stem-like cells, with potential implications for the diagnosis and treatment of breast cancer patients. Cancer Res; 76(13); 3916–28. ©2016 AACR.

Usage metrics

    Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC